List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2829507/publications.pdf Version: 2024-02-01



ΠΕΙΙΑ Π'ΑνοιΑ

#	Article	IF	CITATIONS
1	Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology, 2013, 57, 1078-1087.	3.6	240
2	Intratumoral heterogeneity and clonal evolution in liver cancer. Nature Communications, 2020, 11, 291.	5.8	230
3	Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. Journal of Vascular and Interventional Radiology, 2010, 21, 1205-1212.	0.2	136
4	Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver International, 2015, 35, 1715-1721.	1.9	132
5	Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. European Journal of Surgical Oncology, 2012, 38, 594-601.	0.5	122
6	Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in Nonhuman Primates and Patients. Molecular Therapy, 2016, 24, 1100-1105.	3.7	122
7	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. Journal of Hepatology, 2016, 65, 776-783.	1.8	119
8	Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes/Metabolism Research and Reviews, 2006, 22, 274-283.	1.7	94
9	Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. Liver Transplantation, 2011, 17, 402-408.	1.3	89
10	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 2018, 37, 3740-3752.	2.6	89
11	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. Liver Transplantation, 2013, 19, 937-944.	1.3	87
12	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene, 2021, 40, 140-151.	2.6	77
13	Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. Hpb, 2014, 16, 243-249.	0.1	69
14	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. Scientific Reports, 2018, 8, 11570.	1.6	64
15	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver International, 2015, 35, 1590-1596.	1.9	55
16	Analysis of Prognostic Factors After Yttrium-90 Radioembolization of Advanced Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1441-1448.	0.4	54
17	Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages. Annals of Surgical Oncology, 2011, 18, 1964-1971.	0.7	53
18	Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. Liver Transplantation, 2017, 23, 498-509.	1.3	51

#	Article	IF	CITATIONS
19	Safety and Liver Transduction Efficacy of rAAV5-‹i>cohPBGDin Nonhuman Primates: A Potential Therapy for Acute Intermittent Porphyria. Human Gene Therapy, 2013, 24, 1007-1017.	1.4	50
20	Efficacy of Transjugular Intrahepatic Portosystemic Shunt to Prevent Total Portal Vein Thrombosis in Cirrhotic Patients Awaiting for Liver Transplantation. Transplantation Proceedings, 2012, 44, 2603-2605.	0.3	39
21	The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1185-1198.	1.8	35
22	A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepato-Gastroenterology, 2009, 56, 1683-8.	0.5	33
23	Transarterial therapies for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2011, 12, 1057-1073.	0.9	32
24	NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma. Oncotarget, 2017, 8, 40967-40981.	0.8	29
25	Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells. Translational Research, 2017, 188, 80-91.e2.	2.2	28
26	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. Transplant Immunology, 2015, 33, 110-116.	0.6	25
27	Factors related to increased resting energy expenditure in men with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2016, 28, 139-145.	0.8	25
28	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. Gut, 2022, 71, 2069-2080.	6.1	24
29	The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection. Current Pharmaceutical Design, 2004, 10, 2081-2092.	0.9	23
30	Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. Clinical Immunology, 2006, 118, 229-232.	1.4	21
31	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver diseaseâ€hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clinical Liver Disease, 2016, 8, 100-104.	1.0	20
32	Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. Annals of Transplantation, 2017, 22, 141-147.	0.5	20
33	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Molecular Therapy - Methods and Clinical Development, 2015, 2, 15006.	1.8	15
34	Controlling Diabetes After Liver Transplantation. Transplantation, 2016, 100, e66-e73.	0.5	15
35	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. PLoS Genetics, 2021, 17, e1009589.	1.5	15
36	Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. Journal of Hepatology, 2011, 55, 828-837.	1.8	14

#	Article	IF	CITATIONS
37	Subsequent Nonmelanoma Skin Cancer after Liver Transplantation. Transplantation Proceedings, 2012, 44, 1568-1570.	0.3	13
38	Lung cancer screening with low-radiation dose computed tomography after liver transplantation. Annals of Transplantation, 2013, 18, 587-592.	0.5	11
39	GS-14-ENVISION, a phase 3 study to evaluate efficacy and safety of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1, in acute hepatic porphyria patients. Journal of Hepatology, 2019, 70, e81-e82.	1.8	10
40	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. Histopathology, 2019, 74, 718-730.	1.6	9
41	Angiogenic Cytokines in Patients Undergoing Antiviral Treatment for Chronic Hepatitis C Virus Infection. Journal of Interferon and Cytokine Research, 2011, 31, 207-210.	0.5	7
42	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Cloneâ€Đependent Release of Circulating Tumor DNA. Hepatology Communications, 2021, 5, 1095-1105.	2.0	7
43	Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease. Histopathology, 2006, 48, 822-830.	1.6	6
44	Is Liver Biopsy Necessary in the Evaluation of a Living Donor for Liver Transplantation?. Transplantation Proceedings, 2014, 46, 3082-3083.	0.3	6
45	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. CardioVascular and Interventional Radiology, 2020, 43, 1165-1172.	0.9	6
46	Lower schooling, higher hepatitis C virus prevalence in Italy: An association dependent on age. Journal of Clinical Virology, 2007, 40, 168-170.	1.6	4
47	V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. CirugÃa Española, 2015, 93, 619-637.	0.1	3
48	Brain ventricular enlargement in human and murine acute intermittent porphyria. Human Molecular Genetics, 2020, 29, 3211-3223.	1.4	3
49	Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation. Revista Espanola De Enfermedades Digestivas, 2011, 103, 142-9.	0.1	3
50	Applicability of Living Donor Liver Transplantation in a Program of Adult Liver Transplantation. Transplantation Proceedings, 2011, 43, 690-691.	0.3	2
51	Prospect and progress of gene therapy in acute intermittent porphyria. Expert Opinion on Orphan Drugs, 2016, 4, 711-717.	0.5	2
52	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. CardioVascular and Interventional Radiology, 2019, 42, 1262-1270.	0.9	2
53	Abstract 1189: Deciphering the impact of immune editing on liver cancer clonal evolution using immunogenomics. Cancer Research, 2018, 78, 1189-1189.	0.4	1
54	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0

#	Article	IF	CITATIONS
55	Abstract 2383: Multiregional RNA sequencing identifies intratumor transcriptomic heterogeneity in a subset of early-stage hepatocellular carcinoma. , 2016, , .		0
56	Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 25-43.	0.1	0
57	Abstract 4393: Integrative molecular analysis of gene expression and methylation reveals 116 putative key regulator genes of human hepatocarcinogenesis. , 2017, , .		0
58	Abstract 402: RNA-sequencing of plasma exosomes reveals specific transcriptomic profiles in patients with hepatocellular carcinoma. , 2019, , .		0